APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Glucagon Like Peptide-1 (GLP-1) Agonists

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Selected research

Market Structure

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173995480325 December 2025185 pages

Choose your research edition.

Industry ResearchGlucagon Like Peptide-1 (GLP-1) Agonists Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.

United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.

Read the full market overview

This report provides an overview of the global Glucagon Like Peptide-1 (GLP-1) Agonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Glucagon Like Peptide-1 (GLP-1) Agonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Glucagon Like Peptide-1 (GLP-1) Agonists market size, projected growth trends, production technologies, key applications, and end-use industries.

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Company

Novo Nordisk

AstraZeneca

Eli Lily

GSK

Sanofi

Bristol-Myers Squibb

Amylin

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type

Exenatied

Liraglutide

Lixisenatide

Albiglutide

Dulaglutide

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Application

Hospital

Pharmacy

Other

Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon Like Peptide-1 (GLP-1) Agonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glucagon Like Peptide-1 (GLP-1) Agonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon Like Peptide-1 (GLP-1) Agonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Glucagon Like Peptide-1 (GLP-1) Agonists market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Glucagon Like Peptide-1 (GLP-1) Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Glucagon Like Peptide-1 (GLP-1) Agonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends Table 2. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers Table 3. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges Table 4. Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints Table 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturers Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers, Product Type & Application Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Exenatied Table 17. Major Manufacturers of Liraglutide Table 18. Major Manufacturers of Lixisenatide Table 19. Major Manufacturers of Albiglutide Table 20. Major Manufacturers of Dulaglutide Table 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2026) & (K Units) Table 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2027-2032) & (K Units) Table 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2021-2026) Table 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2027-2032) Table 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2026) & (K Units) Table 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2027-2032) & (K Units) Table 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2021-2026) Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Pharmacy Table 33. Major Manufacturers of Other Table 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2026) & (K Units) Table 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2027-2032) & (K Units) Table 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2021-2026) Table 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2027-2032) Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2026) & (K Units) Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2027-2032) & (K Units) Table 42. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2021-2026) Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2027-2032) Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2021-2026) & (K Units) Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2021-2026) Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 51. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 52. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 54. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2027-2032) & (K Units) Table 61. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2021-2026) Table 65. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2027-2032) Table 66. Novo Nordisk Company Information Table 67. Novo Nordisk Business Overview Table 68. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 70. Novo Nordisk Recent Development Table 71. AstraZeneca Company Information Table 72. AstraZeneca Business Overview Table 73. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 75. AstraZeneca Recent Development Table 76. Eli Lily Company Information Table 77. Eli Lily Business Overview Table 78. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 80. Eli Lily Recent Development Table 81. GSK Company Information Table 82. GSK Business Overview Table 83. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 85. GSK Recent Development Table 86. Sanofi Company Information Table 87. Sanofi Business Overview Table 88. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 90. Sanofi Recent Development Table 91. Bristol-Myers Squibb Company Information Table 92. Bristol-Myers Squibb Business Overview Table 93. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 95. Bristol-Myers Squibb Recent Development Table 96. Amylin Company Information Table 97. Amylin Business Overview Table 98. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio Table 100. Amylin Recent Development Table 101. Key Raw Materials Table 102. Raw Materials Key Suppliers Table 103. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List Table 104. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Image Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size (2021-2032) & (US$ Million) Figure 4. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (2021-2032) & (K Units) Figure 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price (USD/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Exenatied Image Figure 9. Liraglutide Image Figure 10. Lixisenatide Image Figure 11. Albiglutide Image Figure 12. Dulaglutide Image Figure 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2021-2032) Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Pharmacy Image Figure 21. Other Image Figure 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2021-2032) Figure 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2021-2032) Figure 28. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2032) Figure 30. U.S. Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2032) Figure 35. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2032) Figure 42. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2021-2032) Figure 50. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Figure 61. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Figure 63. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Glucagon Like Peptide-1 (GLP-1) Agonists Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Exenatied
  • Liraglutide
  • Lixisenatide
  • Albiglutide
  • Dulaglutide
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Novo Nordisk
  • AstraZeneca
  • Eli Lily
  • GSK
  • Sanofi
  • Bristol-Myers Squibb
  • Amylin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Dynamics
  1. 2.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
  2. 2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Drivers
  3. 2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Opportunities and Challenges
  4. 2.4 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Restraints
3 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Manufacturers
  1. 3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers (2021-2026)
  3. 3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Glucagon Like Peptide-1 (GLP-1) Agonists Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers, Product Type & Application
  7. 3.7 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Glucagon Like Peptide-1 (GLP-1) Agonists Tier 1, Tier 2, and Tier 3
4 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Type
  1. 4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Type Introduction
  2. 4.1.1 Exenatied
  3. 4.1.2 Liraglutide
  4. 4.1.3 Lixisenatide
  5. 4.1.4 Albiglutide
  6. 4.1.5 Dulaglutide
  7. 4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type
  8. 4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2021-2032)
  10. 4.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2021-2032)
  11. 4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type
  12. 4.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2021-2032)
  14. 4.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2021-2032)
5 Glucagon Like Peptide-1 (GLP-1) Agonists Market by Application
  1. 5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application
  6. 5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2021-2032)
  8. 5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2021-2032)
  9. 5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application
  10. 5.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2021-2032)
  12. 5.3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2021-2032)
6 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region
  1. 6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2021-2032)
  3. 6.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2021-2026)
  4. 6.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region
  1. 7.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region
  2. 7.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2021-2026)
  4. 7.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2027-2032)
  5. 7.1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032)
  8. 7.2.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032)
  11. 7.3.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Novo Nordisk
  2. 8.1.1 Novo Nordisk Company Information
  3. 8.1.2 Novo Nordisk Business Overview
  4. 8.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  6. 8.1.5 Novo Nordisk Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Eli Lily
  14. 8.3.1 Eli Lily Company Information
  15. 8.3.2 Eli Lily Business Overview
  16. 8.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  18. 8.3.5 Eli Lily Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Bristol-Myers Squibb
  32. 8.6.1 Bristol-Myers Squibb Company Information
  33. 8.6.2 Bristol-Myers Squibb Business Overview
  34. 8.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  36. 8.6.5 Bristol-Myers Squibb Recent Developments
  37. 8.7 Amylin
  38. 8.7.1 Amylin Company Information
  39. 8.7.2 Amylin Business Overview
  40. 8.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product Portfolio
  42. 8.7.5 Amylin Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Glucagon Like Peptide-1 (GLP-1) Agonists Value Chain Analysis
  2. 9.1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Glucagon Like Peptide-1 (GLP-1) Agonists Production Mode & Process
  6. 9.2 Glucagon Like Peptide-1 (GLP-1) Agonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors
  9. 9.2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst